According to recent reports in the diabetes news, biopharmaceutical company CureDM Inc. have made a significant breakthrough in the development of their type 1 and type 2 diabetes treatment HIP.
HIP (Human proIslet Peptide) is designed to prevent, ameliorate or even reverse diabetes . The company have reportedly stabilised the treatment to work out the appropriate dosage for humans. The company developed the peptide from a specific human gene that populated the pancreas with islet cells.
The CEO of CureDM, Lorain Upham, reportedly commented: “Meeting this milestone has a significant impact on the commercial value of Human proIslet Peptide. Not only does this mean lower costs associated with the manufacture and commercializatio, but also potentially better safety and tolerability outcomes in human trials.”
The company have applied with the FDA for approval of human studies.
